النقاط الرئيسية
- CA-125 (Cancer Antigen 125) is a protein biomarker found at elevated levels in approximately 80% of advanced ovarian cancers and 50% of early-stage cases.
- A normal CA-125 level is below 35 U/mL, but elevated readings do not automatically indicate cancer — many benign conditions can raise CA-125.
- Common benign causes of elevated CA-125 include endometriosis, menstruation, pelvic inflammatory disease, uterine fibroids, and liver disease.
- Persistent symptoms such as bloating, pelvic pain, difficulty eating, and urinary urgency lasting more than two weeks warrant a CA-125 test and gynecological evaluation.
- No fasting is required for a CA-125 blood test; however, scheduling outside your menstrual period improves result accuracy.
- At DCDC in Dubai Healthcare City, CA-125 results are available within 24–48 hours, with on-site sample collection and same-day appointments.
Ovarian cancer is often called the "silent killer" because its early symptoms mimic common digestive and urinary complaints. The CA-125 blood test measures Cancer Antigen 125, a protein biomarker that can become elevated in the presence of ovarian cancer and several other conditions. Understanding when to request this test, how to interpret your results, and what symptoms should prompt further investigation can play a critical role in early detection and treatment outcomes.
At Doctors Clinic Diagnostic Center (DCDC) in Dubai Healthcare City, our MOHAP-licensed laboratory offers same-day CA-125 testing with results delivered within 24–48 hours. Whether your physician has recommended a CA-125 test as part of a routine screening panel, or you are experiencing symptoms that concern you, this guide covers everything you need to know about the CA-125 ovarian cancer marker — from normal ranges and common causes of elevation to the symptoms that should prompt you to see a specialist in Dubai.
What Is the CA-125 Test and How Does It Work?
CA-125, or Cancer Antigen 125, is a glycoprotein found on the surface of many cell types, including cells lining the ovaries, fallopian tubes, uterus, and peritoneum. When these cells are irritated, damaged, or grow abnormally, they can release CA-125 into the bloodstream in measurable quantities.
The CA-125 test is a simple blood draw that quantifies the level of this protein in your serum. It is not a definitive diagnostic test for ovarian cancer on its own; rather, it is used alongside imaging studies (such as transvaginal ultrasound), physical examinations, and clinical history to build a complete picture. Physicians use the CA-125 test for four main purposes:
- Screening in high-risk women: Women with a strong family history of ovarian or breast cancer, or those carrying BRCA1/BRCA2 mutations, may benefit from regular CA-125 monitoring alongside transvaginal ultrasound.
- Diagnostic support: When a pelvic mass is identified on imaging, the CA-125 level helps clinicians assess the likelihood that the mass is malignant versus benign.
- Treatment monitoring: During chemotherapy for ovarian cancer, declining CA-125 levels indicate a positive response, while rising levels may signal treatment resistance.
- Recurrence detection: After successful ovarian cancer treatment, periodic CA-125 testing can detect recurrence months before symptoms or imaging abnormalities appear.
For a broader overview of how tumor markers are used across different cancer types, see our guide on blood tests for cancer and tumor markers explained.
CA-125 Normal Range and What Elevated Levels Mean
The widely accepted normal reference range for CA-125 is below 35 U/mL. However, interpreting CA-125 results requires clinical context. A single elevated reading does not confirm cancer, just as a normal reading does not rule it out entirely.
CA-125 Reference Ranges
| CA-125 Level (U/mL) | Interpretation | Typical Next Steps |
|---|---|---|
| Below 35 | Normal range | Routine follow-up; no further action unless symptoms persist |
| 35 – 100 | Mildly elevated | Repeat test in 4–6 weeks; evaluate for benign causes (endometriosis, fibroids, infection) |
| 100 – 200 | Moderately elevated | Transvaginal ultrasound; gynecological consultation; consider additional markers (HE4) |
| 200 – 500 | Significantly elevated | Urgent imaging and specialist referral; further workup for malignancy |
| Above 500 | Highly elevated | Strong suspicion of advanced ovarian cancer or extensive peritoneal disease; immediate oncology referral |
CA-125 interpretation guide. Levels should always be interpreted alongside clinical history, imaging, and physical examination.
It is important to note that approximately 20% of advanced ovarian cancers do not produce elevated CA-125, and 50% of early-stage ovarian cancers have normal CA-125 levels. This is why the test is most valuable when combined with other diagnostic tools rather than used in isolation.
Ovarian Cancer Symptoms: When to Request a CA-125 Test
Ovarian cancer symptoms are often vague and easily attributed to other conditions, which is why awareness is so critical. The following symptom checklist, adapted from guidelines published by the American Cancer Society and the UK's National Health Service, outlines the warning signs that should prompt you to consult a gynaecologist and request a CA-125 test in Dubai.
Primary Warning Signs (Persistent for 2+ Weeks)
- Persistent bloating: A feeling of fullness or abdominal swelling that does not come and go with your menstrual cycle and lasts most days for two weeks or longer.
- Pelvic or abdominal pain: Dull, aching, or sharp pain in the lower abdomen or pelvis that is not related to menstruation or a known condition.
- Difficulty eating or feeling full quickly: A noticeable decrease in appetite or feeling uncomfortably full after eating only a small amount.
- Urinary urgency or frequency: Needing to urinate more often or more urgently than usual, without a urinary tract infection.
Additional Symptoms to Monitor
- Unexplained weight loss or gain: Significant changes in weight without alterations to diet or exercise.
- Changes in bowel habits: New-onset constipation or diarrhoea lasting more than a few days.
- Fatigue: Persistent, unusual tiredness that does not improve with rest.
- Back pain: Lower back pain that is not related to musculoskeletal causes.
- Abnormal vaginal bleeding: Bleeding between periods or post-menopausal bleeding.
- Pain during intercourse: New or worsening pain during sexual activity.
If you experience any combination of these symptoms persistently for more than two to three weeks, it is important to see a gynaecologist rather than dismissing them. Early detection significantly improves ovarian cancer survival rates, with five-year survival exceeding 90% when the disease is caught at Stage I.
Self-Assessment: Should You Get a CA-125 Test?
Consider the following questions. If you answer "yes" to two or more, discussing a CA-125 test with your doctor is strongly recommended:
- Have you experienced persistent bloating, pelvic pain, or urinary changes for more than two weeks?
- Do you have a first-degree relative (mother, sister, daughter) who was diagnosed with ovarian or breast cancer?
- Have you been diagnosed with endometriosis or experienced recurrent ovarian cysts?
- Are you over 50 and experiencing new, unexplained abdominal or pelvic symptoms?
- Have you tested positive for a BRCA1 or BRCA2 gene mutation?
- Have you had a previous CA-125 test that returned elevated results, and you have not followed up?
- Are you currently undergoing or have you completed treatment for ovarian cancer and need monitoring?
Women with endometriosis symptoms or a history of ovarian cysts should be aware that these conditions can elevate CA-125 levels independently of cancer, making clinical context essential for accurate interpretation.
When to See a Doctor: Urgency Guide for CA-125 Testing
Not every symptom requires an emergency visit, but knowing the appropriate level of urgency helps you take timely action. Below is a practical guide for women in Dubai considering a CA-125 test.
Urgent (Within 48 Hours)
- Rapidly increasing abdominal distension with shortness of breath (possible ascites)
- Severe, sudden pelvic pain with nausea or vomiting
- Post-menopausal vaginal bleeding
- A pelvic mass identified on imaging with unknown pathology
Soon (Within 1–2 Weeks)
- Persistent bloating or pelvic discomfort lasting more than two weeks
- Unexplained weight loss combined with appetite changes
- Family history of ovarian cancer with new symptoms
- Previously elevated CA-125 requiring follow-up testing
Routine (At Your Next Appointment)
- Annual screening for high-risk women (BRCA carriers, strong family history)
- Post-treatment surveillance for ovarian cancer survivors
- General wellness check with a comprehensive women's health panel
- Baseline CA-125 measurement for future comparison
Benign Conditions That Can Elevate CA-125
One of the most important things to understand about the CA-125 test is that elevated levels are frequently caused by non-cancerous conditions. This is why an elevated result should prompt further investigation rather than panic. Common benign causes include:
- Endometriosis: One of the most common causes of mildly to moderately elevated CA-125 in premenopausal women. Levels often correlate with disease severity.
- Menstruation: CA-125 can fluctuate during the menstrual cycle, with levels typically peaking during menstruation. This is why testing is recommended outside your period.
- Pelvic inflammatory disease (PID): Active infection and inflammation in the reproductive tract can release CA-125 into the bloodstream.
- Uterine fibroids: Large or multiple fibroids can cause mild CA-125 elevation.
- Liver disease: Cirrhosis and hepatitis can significantly elevate CA-125, sometimes to levels above 100 U/mL.
- Ovarian cysts: Functional and complex ovarian cysts can raise CA-125, particularly if they rupture.
- Pregnancy (first trimester): CA-125 is physiologically elevated in early pregnancy.
- Recent abdominal or pelvic surgery: Peritoneal irritation from recent surgery can transiently elevate CA-125.
Because of these overlapping causes, your gynaecologist will interpret CA-125 results within the context of your complete medical history, physical examination, and imaging findings. A single elevated reading is rarely sufficient to make a diagnosis.
CA-125 Test Preparation and Procedure
The CA-125 test is one of the simplest blood tests you can have. Here is what you need to know before your appointment:
- No fasting required: You can eat and drink normally before your CA-125 blood draw.
- Timing matters: If possible, schedule your test outside your menstrual period to avoid cycle-related fluctuations. Mid-cycle (days 10–20) is generally ideal.
- Inform your doctor: Let your physician know about any current medications, recent surgeries, known endometriosis, active infections, or pregnancy, as these can affect interpretation.
- The procedure: A trained phlebotomist draws a small blood sample from a vein in your arm. The draw takes less than five minutes.
- After the test: You can resume all normal activities immediately. There is no recovery time needed.
Book Your CA-125 Test at DCDC
Walk-in or scheduled appointments available at our Dubai Healthcare City laboratory. No fasting required — get your results within 24–48 hours.
MOHAP Licensed | 4.8/5 Google Rating | 20+ Insurance Partners | Free Parking
What to Expect at DCDC: Your CA-125 Testing Experience
At Doctors Clinic Diagnostic Center, located in Building 64, Block A of the Al Razi Medical Complex in Dubai Healthcare City, the CA-125 testing process is designed to be efficient and comfortable. Most patients complete the entire visit in under 30 minutes.
- Step 1 — Registration: Check in at reception with your Emirates ID and insurance card. DCDC partners with over 20 insurance providers including Daman, AXA, and Bupa for direct billing, so out-of-pocket costs are often minimal.
- Step 2 — Consultation (if needed): If you are visiting without a referral, a brief gynecology consultation with Dr. Parisa Dini or another specialist can determine whether the CA-125 test is appropriate and which additional markers to include.
- Step 3 — Sample collection: Our on-site laboratory collects your blood sample. The average wait time at DCDC is 15 minutes, and the blood draw itself takes under five minutes.
- Step 4 — Results: CA-125 results are typically available within 24–48 hours. You will receive them through our patient portal, and a follow-up consultation can be arranged to discuss the findings.
- Step 5 — Follow-up: If your results are elevated, Dr. Dini can arrange further investigations such as transvaginal ultrasound, additional tumor markers (HE4, CEA), or referral to a gynecological oncologist — all within the DHCC medical ecosystem.
"I encourage women in Dubai — especially those over 40 or with a family history of ovarian or breast cancer — not to ignore persistent abdominal symptoms," says Dr. Parisa Dini, OB-GYN at DCDC. "A CA-125 test is a quick, painless blood draw that can provide early warning signs. While an elevated result does not always mean cancer, it does mean we should investigate further. Early detection remains our most powerful tool in improving ovarian cancer outcomes."
CA-125 Test Cost in Dubai: Pricing Guide
The cost of a CA-125 test in Dubai varies depending on the facility and whether additional tests are bundled. Below is a general pricing guide for CA-125-related services at DCDC. Most tests are covered partially or fully by major insurance plans through direct billing.
| Service | Price Range (AED) | Includes |
|---|---|---|
| CA-125 Blood Test | From AED 200–350 | Single tumor marker, blood draw, results within 24–48 hours |
| Women's Cancer Screening Panel | From AED 500–900 | CA-125, CEA, CA 15-3, CA 19-9, AFP, CBC, and physician review |
| Gynecology Consultation | From AED 250–400 | Clinical assessment, symptom evaluation, test ordering, and follow-up plan |
| Transvaginal Ultrasound | From AED 300–500 | Pelvic imaging to complement CA-125 results and evaluate ovarian morphology |
| Comprehensive Women's Health Panel | From AED 800–1,400 | Tumor markers, hormonal profile, thyroid function, CBC, metabolic panel, and consultation |
Prices are approximate and may vary based on insurance coverage. DCDC offers direct billing with 20+ insurance partners.
For the most accurate pricing based on your insurance plan, contact DCDC reception or send a WhatsApp message. The clinic is open Saturday through Thursday from 8 AM to 10 PM and Friday from 9 AM to 9 PM, with multilingual staff available in Arabic, English, Farsi, Urdu, and Hindi.
CA-125 and Ovarian Cancer Screening: Who Should Be Tested?
Current medical guidelines from organisations such as the American College of Obstetricians and Gynecologists (ACOG) do not recommend universal CA-125 screening for average-risk women. However, targeted screening is recommended for specific populations.
High-Risk Groups Who Should Consider Regular CA-125 Testing
- BRCA1/BRCA2 mutation carriers: Women with confirmed hereditary breast and ovarian cancer syndrome should begin CA-125 monitoring from age 30–35, typically combined with transvaginal ultrasound every six months.
- Strong family history: Two or more first-degree relatives with ovarian cancer, or a family history pattern suggestive of Lynch syndrome (hereditary nonpolyposis colorectal cancer).
- Personal history of breast cancer: Women previously treated for breast cancer have a modestly increased risk of ovarian cancer, particularly if diagnosed before age 50.
- Known pelvic mass: When imaging identifies an ovarian mass of uncertain nature, CA-125 helps stratify the risk of malignancy and guide surgical planning.
- Ovarian cancer survivors: Post-treatment surveillance with serial CA-125 measurements can detect recurrence early, often before clinical symptoms reappear.
For comprehensive screening beyond ovarian cancer, explore our cancer screening guide for Dubai, which covers recommended tests by age group and risk profile.
Understanding Your CA-125 Results: Next Steps After Testing
Receiving your CA-125 results can feel anxiety-inducing, especially if the numbers are elevated. Here is a practical framework for understanding what comes next.
If Your CA-125 Is Normal (Below 35 U/mL)
A normal result is reassuring, but it does not guarantee the absence of ovarian cancer. If your symptoms persist, your gynaecologist may recommend additional investigations such as transvaginal ultrasound, a CT scan, or the Risk of Ovarian Malignancy Algorithm (ROMA), which combines CA-125 with HE4 for improved accuracy. Continue attending regular women's health screenings as recommended for your age and risk profile.
If Your CA-125 Is Mildly Elevated (35–100 U/mL)
Mild elevation is the most common scenario and is frequently caused by benign conditions. Your doctor will likely recommend repeating the test in four to six weeks and may order a pelvic ultrasound. If you are premenopausal, conditions such as endometriosis, fibroids, or a recent menstrual period are the most probable explanations.
If Your CA-125 Is Significantly Elevated (Above 100 U/mL)
Higher elevations warrant prompt investigation. Your gynaecologist will typically order transvaginal ultrasound, possibly a CT scan of the abdomen and pelvis, and additional blood markers. In postmenopausal women, a CA-125 above 100 U/mL with a suspicious pelvic mass carries a high probability of malignancy and usually leads to referral to a gynecological oncologist.
Serial Monitoring (Trending Over Time)
Often more informative than a single value, the trend of CA-125 over sequential tests provides critical clinical insight. A steadily rising CA-125, even within the normal range, may be more concerning than a single mildly elevated reading that remains stable. This is why your doctor may request repeat testing at defined intervals.
CA-125 Test Limitations and Complementary Tests
While the CA-125 test is a valuable tool, it has well-documented limitations that every patient should understand:
- Limited sensitivity in early-stage disease: Only about 50% of Stage I ovarian cancers produce elevated CA-125, reducing its effectiveness as a standalone early screening tool.
- Low specificity in premenopausal women: Many benign gynaecological conditions elevate CA-125 in younger women, leading to false positives that may cause unnecessary anxiety and procedures.
- Not elevated in all ovarian cancer subtypes: Mucinous and clear cell ovarian carcinomas are less likely to produce CA-125 than the more common serous subtype.
- Influenced by non-gynaecological conditions: Liver disease, heart failure, and pleural effusions can all elevate CA-125 independently of any ovarian pathology.
To overcome these limitations, clinicians frequently combine CA-125 with complementary tests:
- HE4 (Human Epididymis Protein 4): A newer biomarker that is less affected by benign conditions. Combined with CA-125 in the ROMA algorithm, it improves diagnostic accuracy.
- Transvaginal ultrasound: Provides direct visualization of ovarian morphology and can identify suspicious masses, cysts, or changes in blood flow.
- CT or MRI imaging: Used when initial findings are suspicious, to assess the extent of disease and guide surgical planning.
- Genetic testing (BRCA1/BRCA2): Identifies hereditary risk factors that inform screening frequency and preventive strategies.
Ovarian Cancer Risk Factors and Prevention in Dubai
Understanding your personal risk factors helps you and your doctor determine the appropriate screening strategy. Ovarian cancer risk factors include both modifiable and non-modifiable elements.
Non-Modifiable Risk Factors
- Age: Ovarian cancer risk increases with age, with the majority of cases diagnosed in women over 50. The median age at diagnosis is 63.
- Genetics: BRCA1 mutations carry a 35–70% lifetime risk of ovarian cancer; BRCA2 mutations carry a 10–30% risk.
- Family history: A first-degree relative with ovarian cancer approximately doubles your risk.
- Reproductive history: Women who have never been pregnant (nulliparity) have a slightly higher risk.
- Endometriosis: Associated with a 2–3 times increased risk of certain ovarian cancer subtypes (endometrioid and clear cell).
Protective Factors
- Oral contraceptive use: Five or more years of combined oral contraceptive use reduces ovarian cancer risk by approximately 50%, with protection lasting decades after stopping.
- Pregnancy and breastfeeding: Each full-term pregnancy and extended breastfeeding period modestly reduces risk.
- Tubal ligation or salpingectomy: Surgical removal or ligation of the fallopian tubes significantly reduces ovarian cancer risk.
Dubai residents have access to world-class screening and prevention resources. Regular gynaecological check-ups, awareness of family history, and timely investigation of symptoms are the cornerstones of ovarian cancer prevention. Women who are concerned about their risk can discuss personalised screening plans with a gynaecologist at DCDC, conveniently located in the heart of Dubai Healthcare City.
CA-125 in the Context of Women's Cancer Screening
The CA-125 test is just one component of a comprehensive women's cancer screening strategy. Depending on your age, risk factors, and medical history, your gynaecologist may recommend combining CA-125 with other cancer screening tests for a more complete assessment.
| Screening Test | Cancer Type | Recommended Frequency |
|---|---|---|
| CA-125 Blood Test | Ovarian cancer | Annually for high-risk women; as needed for symptomatic patients |
| Pap Smear / HPV Test | Cervical cancer | Every 3–5 years for women aged 25–65 |
| Mammography | Breast cancer | Annually from age 40 (earlier if high-risk) |
| Colonoscopy | Colorectal cancer | Every 10 years from age 45 (earlier if family history) |
| Skin Check | Skin cancer | Annually or as recommended based on risk factors |
Recommended cancer screening schedule for women. Always consult your physician for personalised recommendations.
For cervical cancer screening specifically, read our detailed guides on cervical cancer screening in Dubai and the Pap smear test to understand the recommended schedule and what to expect.
Schedule Your Women's Health Screening
From CA-125 and tumor markers to Pap smears and mammography referrals, DCDC offers comprehensive women's cancer screening with same-day appointments in Dubai Healthcare City.
Building 64, Block A, Al Razi Medical Complex | Sat–Thu 8 AM–10 PM, Fri 9 AM–9 PM | Free Parking
Frequently Asked Questions About the CA-125 Test in Dubai
Below are answers to the most common questions our patients ask about the CA-125 ovarian cancer marker test at DCDC.
خدمات ذات صلة في DCDC
رعاية متخصصة وتشخيص متقدم في مدينة دبي الطبية
الأسئلة الشائعة
Final Thoughts
The CA-125 test is a valuable but imperfect tool in the fight against ovarian cancer. Its greatest strength lies not in providing a definitive diagnosis from a single blood draw, but in contributing critical data points that, combined with clinical assessment, imaging, and patient history, help gynaecologists make informed decisions about further investigation and treatment.
If you are experiencing persistent symptoms such as bloating, pelvic pain, urinary changes, or unexplained weight loss, do not dismiss them. A simple CA-125 blood test, available with same-day appointments at DCDC in Dubai Healthcare City, can be the first step toward peace of mind or early intervention. With a 4.8/5 Google rating from over 1,000 verified reviews and a 98% patient satisfaction rate, DCDC is committed to making women's health screening accessible, efficient, and compassionate.
Speak with Dr. Parisa Dini or another member of our gynaecology team to discuss whether CA-125 testing is appropriate for you. Early detection saves lives, and taking that first step is always the most important one.
المصادر والمراجع
تمت مراجعة هذا المقال من قبل فريقنا الطبي ويستند إلى المصادر التالية:
- American College of Obstetricians and Gynecologists (ACOG) — Practice Bulletin: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer
- NHS — Ovarian Cancer: Symptoms and Diagnosis
- Mayo Clinic — CA 125 Test: What You Need to Know
- Cancer Research UK — Ovarian Cancer Risks and Causes
- World Health Organization (WHO) — Cancer Fact Sheets: Ovarian Cancer
- American Cancer Society — Ovarian Cancer Early Detection, Diagnosis, and Staging
يتم مراجعة المحتوى الطبي على هذا الموقع من قبل أطباء مرخصين من هيئة الصحة. اطلع على سياستنا التحريرية لمزيد من المعلومات.
كتبه
Dr. Parisa Dini
Obstetrician & Gynaecologist
MD, OB-GYN
Dr. Parisa Dini is an Obstetrician and Gynaecologist at Doctors Clinic Diagnostic Center (DCDC) in Dubai Healthcare City.
Related Articles
Blood Tests for Cancer: Tumor Markers Explained
Cancer Screening Dubai
Women's Health Screening
Ovarian Cyst Symptoms & Treatment
More in Women's Health
Mammogram vs Breast Ultrasound Dubai (2026)
اقرأ المزيدEndometriosis Dubai: Symptoms & Diagnosis (2026)
اقرأ المزيد
Maternity Package Cost Dubai: From AED 1,500 (2026)
اقرأ المزيدGynecologist Cost Dubai: From AED 500 (2026)
اقرأ المزيدPerimenopause Symptoms Dubai: Signs & Care (2026)
اقرأ المزيد
Pregnancy Scan Schedule Dubai: Trimester Guide (2026)
اقرأ المزيد© 2026 Doctors Clinic Diagnostic Center (DCDC), Dubai Healthcare City. Originally published at https://doctorsclinicdubai.ae/blog/ca-125-ovarian-cancer-test-dubai. All rights reserved. Unauthorized reproduction is prohibited.